Statin Use and Incident Heart Failure by Race and Cardiovascular Disease Risk in a Real World Primary Prevention Cohort

被引：0
|
作者：
Hay, Eli J.
Zhu, Jianhui
Thoma, Floyd W.
Marroquin, Oscar C.
Muluk, Pallavi
Johnson, Amber E.
Countouris, Malamo E.
Smith, Anson J.
Saeed, Gul J.
Al Rifai, Mahmoud
Saeed, Anum
Mulukutla, Suresh R.
机构：
来源：
CIRCULATION | 2022年 / 146卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A14412
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Effect of fitness on incident diabetes from statin use in primary prevention
    Radford, Nina B.
    DeFina, Laura F.
    Barlow, Carolyn E.
    Kerr, Alice
    Chakravorty, Ripa
    Khera, Amit
    Levine, Benjamin D.
    ATHEROSCLEROSIS, 2015, 239 (01) : 43 - 49
  • [32] Appropriate primary prevention of cardiovascular disease: does this mean more or less statin use?
    Smith, Jane
    AUSTRALIAN PRESCRIBER, 2011, 34 (06) : 169 - 172
  • [33] Audit of statin use for primary prevention of cardiovascular disease in people with Type 1 diabetes
    Maxwell, K. L.
    Munir, A.
    DIABETIC MEDICINE, 2015, 32 : 103 - 104
  • [34] STATIN USE FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN THE ELDERLY
    Spencer-Bonilla, Gabriela
    Chung, Sukyung
    Heidenreich, Paul A.
    Palaniappan, Latha P.
    Rodriguez, Fatima
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1891 - 1891
  • [35] Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease
    Thanassoulis, George
    Williams, Ken
    Altobelli, Kathleen Kimler
    Pencina, Michael J.
    Cannon, Christopher P.
    Sniderman, Allan D.
    CIRCULATION, 2016, 133 (16) : 1574 - +
  • [36] Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease
    Thanassoulis, George
    Williams, Ken
    Altobelli, Kathleen K.
    Pencina, Michael J.
    Cannon, Christopher P.
    Sniderman, Allan D.
    Sniderman, Allan D.
    CIRCULATION, 2016, 133
  • [37] Statin Use and Eligibility for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Adults at Borderline or Intermediate Risk in the United States
    Hammond, Michael M.
    Cameron, Natalie A.
    Ning, Hongyan
    Bah, Imani
    Beltrame, Kaitlyn
    Khan, Sadiya S.
    Shah, Nilay S.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (08):
  • [38] Trends and Gaps in Statin Use for Cardiovascular Disease Prevention in Type 2 Diabetes: A Real-World Study in Shanghai, China
    Jing, Renjie
    Yao, Huayan
    Yan, Qun
    Xue, Yanbin
    Sun, Wen
    Lu, Ping
    Zhang, Zizheng
    Xie, Rui
    Cui, Bin
    Feng, Bo
    ENDOCRINE PRACTICE, 2023, 29 (10) : 747 - 753
  • [39] Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database
    Lo, Shih-Chang
    Kornelius, Edy
    Liao, Pei-Lun
    Huang, Jing-Yang
    Yang, Yi-Sun
    Huang, Chien-Ning
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 200
  • [40] Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus
    Koo, Bo Kyung
    DIABETES & METABOLISM JOURNAL, 2014, 38 (01) : 32 - 34
12345